Scott Struthers, Crinetics CEO
March 19, 2024 07:14 AM EDT
R&D

Cri­net­ics re­ports sec­ond PhI­II win for acromegaly drug, eyes 2025 launch

Katherine Lewin

News Reporter

Cri­net­ics’ sec­ond Phase III tri­al in­ves­ti­gat­ing its drug pal­tuso­tine in a rare hor­mon­al dis­or­der read out topline da­ta on Tues­day, with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times